213: Quantitative Regression of qFibrosis with Resmetirom in MAESTRO-NASH Trial

Send us Fan Mail Paper Discussed in this Episode: Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial. Schattenberg JM, Bedossa P, Guy CD, et al. Journal of Hepatology 2026; Episode Summary: In this deep dive, we explore how artificial intelligence is revolutionizing the way we measure liver disease recovery. We examine a groundbreaking 2026 Phase III clinical trial (MAESTRO-NASH) that compared traditional human pathologist staging against an AI-driven digital pathology tool called qFibrosis. The study forces us to reconsider our clinical gold standards by asking: what if AI can detect subtle biological healing that the experienced human eye completely misses? In This Episode, We Cover: • The Silent Epidemic: Understanding Metabolic dysfunction-associated steatohepatitis (MASH), a progressive, active form of fatty liver disease linked to cardiovascular risk and cirrhosis. We discuss why precisely tracking the reversal of liver fibrosis is crucial for patient outcomes. • The "Ordinal" Problem: Why the current "gold standard"—human pathologists assigning a simple ordinal score (like Stage F1, F2, or F3)—is subjective and fails to capture the dynamic, nuanced reality of fibrosis progression and regression. • The AI Microscope (SHG & qFibrosis): ◦ SHG (Second Harmonic Generation): An imaging technique that takes advantage of the physical properties of collagen to map out the three-dimensional architecture of the liver. ◦ qFibrosis: An AI-driven analysis tool that evaluates up to 184 distinct features of liver collagen (like string length, width, and intersections) across different regions of the liver lobule, providing a continuous, hyper-detailed assessment rather than a basic category. • The Showdown - Humans vs. AI: Using data from 966 patients in the MAESTRO-NASH trial, we compare how human pathologists and the AI evaluated liver biopsies at baseline and week 52 to test the efficacy of the drug resmetirom. • The AI's "Aha!" Moment (Seeing the Invisible): The most shocking finding of the study occurred in the "non-responder" group. Even when human consensus reads declared certain patients had no histological improvement, the AI detected significant, continuous reductions in liver fibrosis (qFC scores). The digital pathology tool was able to pick up on subthreshold, early matrix remodeling that was entirely invisible to standard manual scoring. • Mapping the Liver's Healing: The AI proved its biological accuracy by successfully linking its spatial data to real-world clinical outcomes. The AI found that specific regional changes—particularly in the portal tract—strongly correlated with non-invasive liver stiffness tests like Magnetic Resonance Elastography (MRE). Key Takeaway: AI isn't here to replace human pathologists; it is a hyper-sensitive tool designed to uncover hidden data patterns. By detecting continuous, region-specific changes in liver collagen, AI digital pathology can identify early therapeutic responses to MASH treatments that traditional staging misses, fundamentally changing how we track disease reversal and personalize medicine Support the show Get the "Digital Pathology 101" FREE E-book and join us!

You can listen to 213: Quantitative Regression of qFibrosis with Resmetirom in MAESTRO-NASH Trial online on Radio and Podcast. Open the player on this page to stream the available audio.

213: Quantitative Regression of qFibrosis with Resmetirom in MAESTRO-NASH Trial is an episode from Digital Pathology Podcast by Aleksandra Zuraw, DVM, PhD.

This episode is 19:26 long.

This episode was published on Apr 2, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Digital Pathology Podcast when more episodes are available from the podcast feed.